Home›Trial›NCT07143669
NCT07143669RECRUITING

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Study Summary

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Conditions
Clonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease
Interventions / Drugs
Screening
View on ClinicalTrials.gov ↗
Sponsor
BPMC
Blueprint Medicines
Oncology
D40/100
Study Details
Enrollment450 participants
Primary Completion—
Lead SponsorBlueprint Medicines Corporation
Data Retrieved2026-04-11 04:08:23.597258+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 450 participants
Sponsor Catalyst Profile

Blueprint Medicines (BPMC) is the sponsoring company for this trial. BiotechSign currently grades this company D (40/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BPMC Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.